STAT

Opinion: Ending tuberculosis will take lower drug prices and a new, improved innovation ecosystem

Mentioning TRIPS flexibilities in the U.N. political declaration on stopping TB won't harm people with the disease, and those who claim otherwise know it won't. @StopTB @TBAlliance
A doctor checks an X-ray film at a public clinic in Lima, Peru, where tuberculosis is a major public health issue.

The United Nations “high-level meeting” on tuberculosis will take place in less than a month and the political declaration that emerges from it will, for better or worse, shape the global response to the world’s deadliest infectious disease for years, perhaps decades, to come. There is a very real risk that the declaration could undermine, rather than improve, access to medicines for the more than 10 million people who fall ill with tuberculosis every year. To prevent this from happening, we must distinguish disagreements that are honest from those that are dishonest.

The content of the political declaration was supposed to have been agreed upon a few months ago, but that didn’t happen. Here’s why: The United States government and pharmaceutical companies are to strip language from the declaration that reminds countries they can use international legal mechanisms to lower the prices of tuberculosis drugs to make them accessible to all people who need them. But countries from the global South with high burdens

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks